NCT03842267已完成3 期
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Gemigliptin 50mg in Patients With Type 2 Diabetes Who Have Inadequate glycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
LG Chem1 个研究点 分布在 1 个国家目标入组 315 人开始时间: 2019年5月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 315
- 试验地点
- 1
- 主要终点
- Changes from baseline HbA1c at week 24
研究概览
简要总结
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with dapagliflozin and metformin
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes mellitus of upper 19 years old at the time of Visit 1 (Screening)
- •Visit 1 (Screening) Patients who had taken Dapagliflozin 10mg/day and Metformin(≥1000mg/day) more than 8 weeks and who have inadequate blood glucose control at Visit 1 (Screening)
- •Patients who have signed an informed consent themselves after receiving explanation about the objectives, methods, effects, etc. of the clinical study
- •Patients who are applicable to one of the three in the following. 1) Surgically infertile patients 2) Postmenopausal female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation 3) Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of contraceptive measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the investigational product
- •Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide
- •Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal implant(Implanon), Vaginal ring
- •Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)
- •Natural methods: Basic body temperature, Ovulation period, Coitus interruptus, Abstinence
排除标准
- •Patients with type 1 diabetes mellitus, Diabetic ketoacidosis, Metabolic acidosis Diabetic coma, Diabetic pre-coma
- •Patients with Gestational diabetes, or secondary diabetes
- •Patients with Body Mass Index(BMI) >40 kg/m2 at the time of Visit 1(Screening)
- •Patients with a history of the following
- •Patients with NYHA Class II~IV congestive heart failure or arrhythmia requiring treatment at the time of Visit 1(Screening)
- •Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy at the time of Visit 1(Screening) (However, those who have been taking thyroid hormone at a fixed dose since previous 4 weeks prior to Visit 1(Screening) and whose TSH level is within the normal range can participate in the study.)
- •Patients with a glomerular filtration rate (eGFR) less than 45 mL/min /1.73 m2, moderate of severe stage renal disease, end-stage renal disease, dialysis at the time of Visit 1(Screening)
- •Patients who are receiving intravenous iodine contrast agents within 48 hours prior to Visit 1(Screening) or planned during the clinical trial period (eg, intravenous urography, venous cholangiography, angiography, computed tomography using contrast media, etc.).
- •Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)
- •Patients on dehydration, diarrhea, and vomiting at the time of Visit 1(Screening)
- •Patients with pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)
- •Patients with a history of myocardial infarction, unstable angina, and Cerebrovascular disease within 12 weeks prior to Visit 1(Screening)
- •Patients who had had a surgical operation within 4 weeks prior to Visit 1(Screening) (excluding minor surgeries without restriction on food and fluid intake) or who are scheduled to have a significant surgery during the study period
- •Patients with a history of alcoholism or drug addiction within 1 years prior to Visit 1(Screening)
- •Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.
- •Patients with the outcomes of the laboratory tests performed at Visit 1(Screening) applicable to the criteria below
- •Bilirubin >2 × upper limit of normal(ULN)
- •AST/ALT >3 × ULN
- •Patients with a history of hypersensitivity reactions to the drugs below
- •Dipeptidyl-peptidase4(DPP4) inhibitors
- •Sodium/glucose co transport-2(SGLT-2) inhibitor
- •Biguanides
- •Patients who were administered the drugs below
- •Patients who had been administered anti-obesity drugs within 12 weeks prior to Visit 1(Screening)
- •Patients who had been administered insulin or GLP-1 analogues within 8 weeks prior to Visit 1(Screening)
- •Patients who had been being administered glucocorticoids, Strong CYP3A4 inducers continuously within 2 weeks prior to Visit 1(Screening) or who are required to take glucocorticoids continuously in the future
- •Patients with positive Serologic results of HBsAg, HCV Ab, HIV Ab test within 4 weeks prior to Visit 1 (Screening) or at Visit 1 (Screening)
- •Patients who have undergone bariatric surgery within the 1 year prior to Visit 1 (Screening) or are scheduled during the trial
- •Patients with a genetic problems such as Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption)
- •Female patients who are pregnant or lactating
- •Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)
- •Patients who are otherwise considered to be ineligible for this study on investigators' judgment
研究组 & 干预措施
Gemigliptin 50mg
Active Comparator
干预措施: Gemigliptin 50mg (Drug)
Gemigliptin Placebo
Placebo Comparator
干预措施: Gemigliptin Placebo (Drug)
结局指标
主要结局
Changes from baseline HbA1c at week 24
时间窗: Baseline (week 0) and week 24
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)Type 2 Diabetes MellitusNCT02831361LG Life Sciences290
Unknown
不适用
Observational Study Gemigliptin in Patients Aged ≥ 65 Years With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT05281029LG Chem3,000
已完成
3 期
Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)Type 2 DiabetesDyslipidemiaNCT02126358LG Life Sciences290
已完成
3 期
Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and MetforminT2DMNCT01990469LG Life Sciences219
已完成
3 期
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and MetforminType 2 DiabetesNCT05504239Handok Inc.235